Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

Interaction analysis of IL-12A and IL-12B polymorphisms with the risk of colorectal cancer

Authors: Ruifen Sun, Fu Jia, Yundan Liang, Lijuan Li, Peng Bai, Fang Yuan, Linbo Gao, Lin Zhang

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

IL-12 is an antitumor cytokine with functions of inhibiting tumor growth, invasion, and metastasis, indicating that IL-12 is a promising candidate for cancer treatment. The aim of this study was to investigate the association of IL-12A rs568408, IL-12A rs2243115, and IL-12B rs3212227 with the susceptibility to colorectal cancer (CRC). Two hundred and fifty-seven histopathologically confirmed CRC patients and 236 age- and gender-matched controls were enrolled. The three polymorphisms were genotyped using a polymerase chain reaction–restriction fragment length polymorphism assay. We found that the IL-12A rs568408 AG/AA genotypes were associated with an increased risk of CRC with an adjusted odds ratio (OR) of 1.66 (95 % confidence interval (CI), 1.11–2.48). Stratified analyses showed that patients carrying the IL-12B rs3212227AC/CC genotypes had a 1.97-fold increased risk of tumor metastasis (OR = 1.97; 95 % CI, 1.04–3.70). Gene–gene interaction analysis showed that subjects carrying the IL-12A rs568408AG/AA and IL-12B rs3212227AA genotypes had a 2.40-fold increased risk of CRC (OR = 2.40; 95 % CI, 1.14–5.07) and individuals carrying the IL-12A rs568408AG/AA and IL-12B rs3212227AC/CC genotypes had a 1.93-fold increased risk of CRC (OR = 1.93; 95 % CI, 1.10–3.41). These findings indicate that IL-12A rs568408 and IL-12B rs3212227 may be related to the development of CRC.
Literature
1.
Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373–80.CrossRefPubMed
2.
Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746–74. 74 e1-4, quiz e12-3.CrossRefPubMed
3.
4.
Lukas M. Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis. 2010;28(4-5):619–24.CrossRefPubMed
5.
Herszenyi L, Barabas L, Miheller P, Tulassay Z. Colorectal cancer in patients with inflammatory bowel disease: the true impact of the risk. Dig Dis. 2015;33(1):52–7.CrossRefPubMed
6.
Basavaraju U, Shebl FM, Palmer AJ, Berry S, Hold GL, El-Omar EM, et al. Cytokine gene polymorphisms, cytokine levels and the risk of colorectal neoplasia in a screened population of Northeast Scotland. Eur J Cancer Prev. 2015;24(4):296–304.CrossRefPubMedPubMedCentral
7.
Cui G, Qi H, Gundersen MD, Yang H, Christiansen I, Sorbye SW, et al. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother. 2015;64(2):181–90.CrossRefPubMed
8.
Gao LB, Rao L, Wang YY, Liang WB, Li C, Xue H, et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis. 2009;30(2):295–9.CrossRefPubMed
9.
Lasek W, Zagozdzon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother. 2014;63(5):419–35.CrossRefPubMedPubMedCentral
10.
Stanilov NS, Miteva LD, Dobreva ZG, Jovchev JP, Cirovski GM, Stanilova SA. Monocytes expression of IL-12 related and IL-10 genes in association with development of colorectal cancer. Mol Biol Rep. 2012;39(12):10895–902.CrossRefPubMed
11.
Nakayama Y, Sako T, Shibao K, Onitsuka K, Nagashima N, Hirata K, et al. Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer. Anticancer Res. 2000;20(6A):4097–102.PubMed
12.
McRae BL, Semnani RT, Hayes MP, van Seventer GA, Type I. IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol. 1998;160(9):4298–304.PubMed
13.
Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999;155(2):537–47.CrossRefPubMedPubMedCentral
14.
Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Jia ZS, et al. Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection. PLoS One. 2011;6(5), e19664.CrossRefPubMedPubMedCentral
15.
Yin XL, Wang N, Wei X, Xie GF, Li JJ, Liang HJ. Interleukin-12 inhibits the survival of human colon cancer stem cells in vitro and their tumor initiating capacity in mice. Cancer Lett. 2012;322(1):92–7.CrossRefPubMed
16.
Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol. 2002;2(6):337–49.CrossRefPubMed
17.
Mazzolini G, Qian C, Xie X, Sun Y, Lasarte JJ, Drozdzik M, et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther. 1999;6(6):514–22.CrossRefPubMed
18.
Hiscox S, Hallett MB, Puntis MC, Jiang WG. Inhibition of cancer cell motility and invasion by interleukin-12. Clin Exp Metastasis. 1995;13(5):396–404.CrossRefPubMed
19.
Shen F, Li JL, Cai WS, Zhu GH, Gu WL, Jia L, et al. Interleukin-12 prevents colorectal cancer liver metastases in mice. Onco Targets Ther. 2013;6:523–6.PubMedPubMedCentral
20.
Malvicini M, Rizzo M, Alaniz L, Pinero F, Garcia M, Atorrasagasti C, et al. A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin Cancer Res. 2009;15(23):7256–65.CrossRefPubMed
21.
Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther. 1998;5(10):1400–9.CrossRefPubMed
22.
Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut. 2011;60(3):341–9.CrossRefPubMed
23.
Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther. 1999;10(5):697–709.CrossRefPubMed
24.
Chen X, Han S, Wang S, Zhou X, Zhang M, Dong J, et al. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res. 2009;15(1):400–5.CrossRefPubMed
25.
Han SS, Cho EY, Lee TS, Kim JW, Park NH, Song YS, et al. Interleukin-12 p40 gene (IL12B) polymorphisms and the risk of cervical cancer in Korean women. Eur J Obstet Gynecol Reprod Biol. 2008;140(1):71–5.CrossRefPubMed
26.
Roszak A, Mostowska A, Sowinska A, Lianeri M, Jagodzinski PP. Contribution of IL12A and IL12B polymorphisms to the risk of cervical cancer. Pathol Oncol Res. 2012;18(4):997–1002.CrossRefPubMed
27.
Navaglia F, Basso D, Zambon CF, Ponzano E, Caenazzo L, Gallo N, et al. Interleukin 12 gene polymorphisms enhance gastric cancer risk in H pylori infected individuals. J Med Genet. 2005;42(6):503–10.CrossRefPubMedPubMedCentral
28.
Yin J, Wang X, Wei J, Wang L, Shi Y, Zheng L, et al. Interleukin 12B rs3212227 T > G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population. Dis Esophagus. 2015;28(3):291–8.CrossRefPubMed
29.
Tao YP, Wang WL, Li SY, Zhang J, Shi QZ, Zhao F, et al. Associations between polymorphisms in IL-12A, IL-12B, IL-12Rbeta1, IL-27 gene and serum levels of IL-12p40, IL-27p28 with esophageal cancer. J Cancer Res Clin Oncol. 2012;138(11):1891–900.CrossRefPubMed
30.
Nieters A, Yuan JM, Sun CL, Zhang ZQ, Stoehlmacher J, Govindarajan S, et al. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer. 2005;103(4):740–8.CrossRefPubMed
31.
Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, et al. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer. 2011;128(7):1692–6.CrossRefPubMed
32.
Huang ZQ, Wang JL, Pan GG, Wei YS. Association of single nucleotide polymorphisms in IL-12 and IL-27 genes with colorectal cancer risk. Clin Biochem. 2012;45(1-2):54–9.CrossRefPubMed
33.
Miteva L, Stanilov N, Deliysky T, Mintchev N, Stanilova S. Association of polymorphisms in regulatory regions of interleukin-12p40 gene and cytokine serum level with colorectal cancer. Cancer Invest. 2009;27(9):924–31.CrossRefPubMed
34.
Lee KM, Shen M, Chapman RS, Yeager M, Welch R, He X, et al. Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei. China Carcinogenesis. 2007;28(7):1437–41.CrossRefPubMed
35.
Ebadi N, Jahed M, Mivehchi M, Majidizadeh T, Asgary M, Hosseini SA. Interleukin-12 and interleukin-6 gene polymorphisms and risk of bladder cancer in the Iranian population. Asian Pac J Cancer Prev. 2014;15(18):7869–73.CrossRefPubMed
36.
Kaarvatn MH, Vrbanec J, Kulic A, Knezevic J, Petricevic B, Balen S, et al. Single nucleotide polymorphism in the interleukin 12B gene is associated with risk for breast cancer development. Scand J Immunol. 2012;76(3):329–35.CrossRefPubMed
37.
Wang J, Nong L, Wei Y, Qin S, Zhou Y, Tang Y. Association of interleukin-12 polymorphisms and serum IL-12p40 levels with osteosarcoma risk. DNA Cell Biol. 2013;32(10):605–10.CrossRefPubMed
38.
Sima X, Xu J, Li Q, Luo L, Liu J, You C. Gene-gene interactions between interleukin-12A and interleukin-12B with the risk of brain tumor. DNA Cell Biol. 2012;31(2):219–23.CrossRefPubMed
39.
Pan XM, Sun RF, Li ZH, Guo XM, Zhang Z, Qin HJ, et al. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol. 2014;35(1):831–5.CrossRefPubMed
40.
Gao LB, Li LJ, Pan XM, Li ZH, Liang WB, Bai P, et al. A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem. 2013;394(3):415–20.CrossRefPubMed
41.
Li L, Pan X, Li Z, Bai P, Jin H, Wang T, et al. Association between polymorphisms in the promoter region of miR-143/145 and risk of colorectal cancer. Hum Immunol. 2013;74(8):993–7.CrossRefPubMed
42.
Li LJ, Pan XM, Sima X, Li ZH, Zhang LS, Sun H, et al. Interactions of interleukin-12A and interleukin-12B polymorphisms on the risk of intracranial aneurysm. Mol Biol Rep. 2012;39(12):11217–23.CrossRefPubMed
43.
Yuzhalin AE, Kutikhin AG. Interleukin-12: clinical usage and molecular markers of cancer susceptibility. Growth Factors. 2012;30(3):176–91.CrossRefPubMed
44.
Kalinski P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol. 1997;159(1):28–35.PubMed
45.
Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133–46.CrossRefPubMed
Metadata
Title
Interaction analysis of IL-12A and IL-12B polymorphisms with the risk of colorectal cancer
Authors
Ruifen Sun
Fu Jia
Yundan Liang
Lijuan Li
Peng Bai
Fang Yuan
Linbo Gao
Lin Zhang
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3685-7

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Research Article

Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro

Research Article

Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma

Research Article

High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer

Research Article

High serum miR-183 level is associated with poor responsiveness of renal cancer to natural killer cells

Research Article

Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer

Research Article

Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits